Cyclohex-1-ensulfonsaeure | 1562-06-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: Cyclohex-1-ensulfonsaeure
• 英文别名: Cyclohexen-(1)-sulfonsaeure-(1)；Cyclohexen-1-sulfonsaeure；Cyclohex-1-en-1-sulfonsaeure；cyclohex-1-enesulfonic acid；Cyclohexene-1-sulfonic acid
• CAS: 1562-06-7
• 化学式: C₆H₁₀O₃S
• 分子量: 162.21
• InChiKey: BAYVBPQZKYSHDL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 barium dihydroxide 作用下， 生成 Cyclohex-1-ensulfonsaeure
  参考文献：
  名称：

  Elimination Reactions in Cyclic Systems. II. cis Eliminations Promoted by the Sulfonate Group¹

  摘要：

  DOI：

  10.1021/ja01610a018

文献信息

• [EN] LANTHIONINE C-LIKE PROTEIN 2 LIGANDS, CELLS PREPARED THEREWITH, AND THERAPIES USING SAME<br/>[FR] LIGANDS DE LA PROTÉINE 2 DE TYPE LANTHIONINE C, CELLULES PRÉPARÉES AVEC CEUX-CI, ET THÉRAPIES LES UTILISANT
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021127472A1

  公开（公告）日：2021-06-24

  Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including autoimmune diseases, inflammatory diseases, chronic inflammatory diseases, diabetes, and infectious diseases, such as lupus, rheumatoid arthritis, type 1 diabetes, inflammatory bowel disease, viral diseases, and nonalcoholic steatohepatitis. The compounds can also be used to generate cells, such as immune cells, for treating the conditions.

  提供的是靶向兰硫氨酸合成酶C样蛋白2途径的化合物。这些化合物可用于治疗多种疾病，包括自身免疫性疾病、炎症性疾病、慢性炎症性疾病、糖尿病和传染性疾病，如狼疮、类风湿性关节炎、1型糖尿病、炎症性肠病、病毒性疾病和非酒精性脂肪肝炎。这些化合物还可用于生成细胞，如免疫细胞，以治疗这些疾病。
• NITROGEN-CONTAINING CONDENSED RING COMPOUNDS HAVING DOPAMINE D3 ANTAGONISTIC EFFECT
  申请人：Shionogi & Co., Ltd.

  公开号：US20190161501A1

  公开（公告）日：2019-05-30

  Novel compounds having D3 receptor antagonistic activity are provided. A compound represented by formula (I): wherein ring A is a heterocycle, X 1 is each independently CR 4a R 4b , X 2 is each independently CR 4c R 4d , Y 1 and Y 2 are each independently a carbon atom or a nitrogen atom, L is —N(R 6 )—C(═O)— or the like, W is cyclyl or the like, R 2 and R 3 are each independently substituted or unsubstituted alkyl or the like, R 1a , R 1b , R 4a to R 4d , and R 6 are each independently hydrogen atoms or the like, p is 1 or 2, q is an integer of 1 to 3, n is an integer of 1 to 4, s is an integer of 0 to 4, or a pharmaceutically acceptable salt thereof.

  提供具有D3受体拮抗活性的新化合物。一种由以下式（I）表示的化合物：其中环A是杂环，X1分别是CR4aR4b，X2分别是CR4cR4d，Y1和Y2分别是碳原子或氮原子，L是—N(R6)—C(═O)—或类似物，W是环烷基或类似物，R2和R3分别是取代或未取代的烷基或类似物，R1a、R1b、R4a到R4d和R6分别是氢原子或类似物，p为1或2，q是1到3的整数，n是1到4的整数，s是0到4的整数，或其药学上可接受的盐。
• Two- and Three-Dimensional Photonic Crystals Built with VLSI Tools
  作者：Shawn-Yu Lin、J.G. Fleming、E. Chow

  DOI：10.1557/mrs2001.157

  日期：2001.8

  The drive toward miniature photonic devices has been hindered by our inability to tightly control and manipulate light. Moreover, photonics technologies are typically not based on silicon and, until recently, only indirectly benefited from the rapid advances being made in silicon processing technology. In the first part of this article, the successful fabrication of three-dimensional (3D) photonic crystals using silicon processing will be discussed. This advance has been made possible through the use of integrated-circuit (IC) fabrication technologies (e.g., very largescale integration, VLSI) and may enable the penetration of Si processing into photonics. In the second part, we describe the creation of 2D photonic-crystal slabs operating at the λ = 1.55 μm communications wavelength. This class of 2D photonic crystals is particularly promising for planar on-chip guiding, trapping, and switching of light.

  朝向微型光子器件的发展受到了我们无法紧密控制和操作光线的限制。此外，光子技术通常不基于硅，直到最近才间接受益于硅处理技术的迅速进步。本文的第一部分将讨论使用硅处理成功制造三维（3D）光子晶体的进展。这一进展得益于集成电路（IC）制造技术（例如，大规模集成，VLSI）的应用，可能使硅处理渗透到光子学中。在第二部分中，我们描述了在λ = 1.55 μm通信波长下运行的2D光子晶体板的创建。这类2D光子晶体对于平面芯片引导、困禁和光开关非常有前景。
• IONIC LIQUID CONTAINING ALLYLSULFONATE ANION
  申请人：Watahiki Tsutomu

  公开号：US20120157680A1

  公开（公告）日：2012-06-21

  PROBLEM: Providing a novel ionic liquid, which is low-cost, environment-friendly, and has low viscosity and melting point. MEANS FOR SOLVING THE PROBLEM: The present invention is the invention of the ionic liquid represented by the general formula [1]: wherein, R 1 to R 3 and n pieces of R 4 each independently represent hydrogen atom or alkyl group having 1 to 4 carbon atoms, R 5 to R 7 each independently represent alkyl group, aralkyl group, or aryl group, R 8 represents alkyl group, aralkyl group, aryl group, or the one represented by the general formula [2]: (wherein T represents alkylene chain having 1 to 8 carbon atoms, n represents 1 or 2, and R 1 to R 7 are the same as the above-described), X represents nitrogen atom or phosphorus atom, n represents 1 or 2. When n is 1, R 3 and R 4 are bound and may form cyclohexene ring together with the adjacent carbon atoms. In addition, when X is nitrogen atom, R 5 to R 7 or R 5 to R 6 may form hetero ring with nitrogen atom binding thereto}.

  问题：提供一种新型离子液体，成本低、环保，并具有低粘度和熔点。 解决问题的方法：本发明是一种由通式[1]表示的离子液体的发明：其中，R1到R3和n个R4分别独立表示氢原子或具有1到4个碳原子的烷基基团，R5到R7分别独立表示烷基基团、芳基烷基基团或芳基基团，R8表示烷基基团、芳基烷基基团、芳基基团或由通式[2]表示的基团：（其中T表示具有1到8个碳原子的烷基链，n表示1或2，R1到R7与上述相同），X表示氮原子或磷原子，n表示1或2。当n为1时，R3和R4结合并且可能与相邻碳原子一起形成环己烯环。此外，当X为氮原子时，R5到R7或R5到R6可能与结合在一起的氮原子形成杂环}。
• [EN] PLXDC2 LIGANDS<br/>[FR] LIGANDS DE PLXDC2
  申请人：LANDOS BIOPHARMA INC

  公开号：WO2021195360A1

  公开（公告）日：2021-09-30

  Provided are compounds that target plexin domain containing 2 (PLXDC2). The compounds can be used to treat conditions such as inflammatory or immune-mediated diseases, diabetes, infectious diseases, and cancers. The compounds can be used to treat such specific conditions as systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, autoimmune encephalitis, diabetic nephropathy, diabetic retinopathy, psoriasis, and inflammatory bowel disease, among other conditions.

  提供了针对含有plexin结构域2（PLXDC2）的化合物。这些化合物可以用于治疗炎症或免疫介导性疾病、糖尿病、传染病和癌症等疾病。这些化合物可以用于治疗系统性红斑狼疮、类风湿关节炎、多发性硬化症、自身免疫性脑炎、糖尿病肾病、糖尿病视网膜病变、银屑病和炎症性肠病等特定疾病。